Biocon’s Cranbury facility in US receives VAI status in FDA inspection

The inspection was conducted by the US FDA between October 6-10, 2025, under current Good Manufacturing Practice (cGMP) regulations. Shares of Biocon Ltd ended at ₹391.50, up by ₹5.40, or 1.40%, on the BSE today, December 18.

Leave a Reply

Your email address will not be published. Required fields are marked *